Kutinova A, Woodward R S, Ricci J F, Brennan D C
University of New Hampshire, Durham, New Hampshire, USA.
Am J Transplant. 2006 Jan;6(1):129-39. doi: 10.1111/j.1600-6143.2005.01156.x.
We compared the graft survival and accumulative costs associated with sepsis and pneumonia pre- and post-transplantation. We analyzed 44 916 first kidney transplants from 1995 to 2001 USRDS where Medicare was the primary payer. We drew five cohorts for each disease from the baseline population: patients who had a disease onset in the first or second years pre-transplantation (cohorts 1 and 2) or post-transplantation (cohorts 3 and 4) and patients who were disease-free (cohort 5). For each cohort, we calculated graft survival and average accumulated Medicare payments (AAMPs) for the two pre- and post-transplantation years. Graft survival: new-onset sepsis and pneumonia both significantly (p <0.01) lowered graft survival during the year of onset. AAMPs: the AAMPs incurred by sepsis- (pneumonia-) free patients during the first and second years post-transplantation were dollar 50,000 and 13,000 (dollar 51,100 and 13,500), respectively. Patients with a sepsis (pneumonia) onset post-transplantation cost on average dollar 48,400 (dollar 38,400) extra (p<0.01). Episodes of sepsis and pneumonia have a strong and independent impact on graft survival and costs.
我们比较了移植前后与脓毒症和肺炎相关的移植物存活率及累积成本。我们分析了1995年至2001年美国肾脏数据系统(USRDS)中以医疗保险作为主要支付方的44916例首次肾脏移植病例。我们从基线人群中为每种疾病抽取了五个队列:在移植前第一年或第二年发病(队列1和队列2)或移植后发病(队列3和队列4)的患者,以及无疾病的患者(队列5)。对于每个队列,我们计算了移植前后两年的移植物存活率和平均累积医疗保险支付金额(AAMPs)。移植物存活率:新发脓毒症和肺炎在发病当年均显著(p<0.01)降低了移植物存活率。AAMPs:移植后第一年和第二年无脓毒症(肺炎)患者产生的AAMPs分别为50000美元和13000美元(51100美元和13500美元)。移植后发生脓毒症(肺炎)的患者平均额外花费48400美元(38400美元)(p<0.01)。脓毒症和肺炎发作对移植物存活率和成本有强烈且独立的影响。